Contract Research Organizations
•44 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (44)
%
| Company | Market Cap | Price |
|---|---|---|
|
Accelerator Drug Development and related CRO capabilities position Thermo Fisher as a Contract Research Organization provider.
|
$198.11B |
$524.80
-1.88%
|
|
IQVIA operates as a Contract Research Organization delivering outsourced R&D services across clinical research and real-world evidence.
|
$34.28B |
$198.17
-2.56%
|
|
Labcorp operates as an outsourced drug development and central-laboratory service provider, i.e., a Contract Research Organization (CRO) in biopharma.
|
$23.26B |
$277.88
-0.11%
|
|
ICON is a Contract Research Organization (CRO) providing outsourced drug development services across all clinical trial phases and expanded scale via the PRA acquisition.
|
$15.15B |
$183.49
-2.46%
|
|
Medpace is a full-service Contract Research Organization (CRO) delivering outsourced clinical development and regulatory services for Phase I–IV trials.
|
$14.41B |
$501.22
-3.28%
|
|
CRL's core business is Contract Research Organization services providing preclinical testing, discovery, and development support for pharma/biotech.
|
$7.38B |
$146.07
-2.26%
|
|
Adesis provides contract research services as a core external-facing offering (contract research organization).
|
$6.53B |
$137.40
-3.36%
|
|
Company engages in collaboration-driven development with big pharma (Takeda/JNJ) and earns development milestones, consistent with Contract Research Organizations.
|
$5.39B |
$87.00
+29.10%
|
|
Provides development services and may engage in early-stage product development for clients as part of its CDMO offerings.
|
$3.53B |
$101.05
-1.93%
|
|
Pharma/academic services revenue indicates outsourced drug development and CRO-like services.
|
$2.03B |
$13.36
-3.68%
|
|
Strategic pharma partnerships and platform-enabled collaborations resemble CRO-like services and outsourced drug-discovery development.
|
$2.02B |
$4.81
-3.99%
|
|
Historically ABCellera provided platform-based discovery services to partners (e.g., Lilly), aligning with CRO/contract research services.
|
$1.45B |
$5.03
+2.86%
|
|
Evotec provides outsourced drug discovery and preclinical development services as a CRO.
|
$1.38B |
$7.28
|
|
IGX subsidiary provides R&D services and license-derived revenue (contract research/outsourced R&D).
|
$1.05B |
$5.23
+1.16%
|
|
Fortrea is a standalone CRO providing outsourced clinical development services.
|
$870.75M |
$9.68
-10.83%
|
|
Datapoints is a contract research organization (CRO) providing outsourced research/data services.
|
$791.35M |
$13.52
-12.04%
|
|
Contract Research Organizations—bioPharma services and clinical trial support.
|
$685.29M |
$22.51
-1.01%
|
|
Absci pursues selective co-development/drug creation partnerships and generates revenue from partner programs, aligning with Contract Research Organizations.
|
$469.42M |
$3.68
-8.46%
|
|
Lifecore engages in development activities alongside manufacturing, aligning with Contract Research Organization services.
|
$240.66M |
$6.50
-2.40%
|
|
Accelerator Laboratory provides contract research, sample testing, and assay development services similar to CRO offerings.
|
$219.00M |
$5.64
-6.00%
|
|
CDMO services are a core outsourced drug development function, aligning with Contract Research Organizations.
|
$191.30M |
$11.04
-8.08%
|
|
Protalix provides R&D services and licenses related milestones to partners, reflecting contract research organization-type activities.
|
$188.17M |
$2.36
+5.36%
|
|
Provides outsourced drug development and preclinical research services (CRO capabilities).
|
$90.10M |
$6.54
-0.46%
|
|
Biopharma Services segment indicates outsourced R&D and clinical testing support typical of Contract Research Organizations.
|
$86.30M |
$8.36
-4.46%
|
|
Nutriband's Pocono Pharmaceuticals segment provides contract development and CRO-style services, aligning with outsourced scientific R&D and development work.
|
$83.77M |
$7.51
-4.21%
|
|
DLH provides science R&D support, clinical research-like services, and epidemiology/data analytics akin to Contract Research Organizations.
|
$79.70M |
$5.61
-1.41%
|
|
Development Services aligns with Contract Research Organizations (CRO) in providing outsourced diagnostic/testing services to biopharma and life sciences.
|
$53.64M |
$7.32
-6.75%
|
|
ABVC engages in outsourced development and collaboration arrangements consistent with Contract Research Organizations (CRO) activities supporting its pipeline.
|
$50.99M |
$3.04
-7.03%
|
|
Offers contract development services (CDMO-like capabilities) to clients for product development and regulatory readiness.
|
$49.10M |
$2.05
-3.76%
|
|
Inotiv is described as a fully integrated Contract Research Organization (CRO) providing nonclinical and analytical drug discovery and development services.
|
$47.75M |
$1.39
-6.08%
|
|
Strategic development services for Lantheus indicate outsourced clinical development capabilities consistent with CRO services.
|
$46.41M |
$7.03
-5.64%
|
|
Provides contract research services related to gene-editing and trait development.
|
$44.36M |
$1.29
-0.77%
|
|
Provides R&D services and contract-like research capabilities leveraging its patents (CRO-like revenue).
|
$35.75M |
$2.02
|
|
Contract Research Organization (development) services complement CDMO offerings.
|
$34.35M |
$4.39
-2.55%
|
|
Internal CRO capabilities reflect Contract Research Organizations service category.
|
$33.48M |
$0.40
-4.29%
|
|
Outsourced R&D/advisory services implied by biotech ventures could align with CRO-like contract research or advisory work.
|
$15.41M |
$0.24
|
|
Contract research/outsourced R&D activity implied by biotech research and licensing.
|
$11.75M |
$1.29
-4.30%
|
|
Collaboration revenue with Moderna indicates the company provides outsourced research/development services, akin to CRO activity.
|
$10.90M |
$0.24
-6.09%
|
|
The strategic merger and near-term revenue from biopharma services align with Contract Research Organizations as a service model.
|
$9.08M |
$1.66
-30.83%
|
|
Provides outsourced drug discovery services and CRO-like capabilities (lab work, data analysis).
|
$8.53M |
$14.32
+1.31%
|
|
Offers contract research and testing support, including stability and third-party clinical testing as part of product development.
|
$6.62M |
$0.03
|
|
Potential outsourcing of research services aligns with Contract Research Organization capabilities (external R&D).
|
$2.10M |
$5.31
-0.56%
|
|
The company uses contract research organizations (e.g., Charles River) and external partnerships for preclinical work, implying outsourcing of R&D services.
|
$391060 |
$0.49
-7.89%
|
|
Potentially provides outsourced R&D-type services or collaborations; categorized under CROs.
|
$229298 |
$0.00
|
Loading industry metrics...
Loading comparison data...
